Please select the option that best describes you:
When (if ever) would you offer adjuvant sunitinib to a patient with chromophobe renal cell carcinoma?
Would you offer for T2N0 G3 resected disease with LVI?
Answer from: Medical Oncologist at Community Practice
To date, evidence is lacking to recommend adjuvant TKIs in chromophobe and other non-clear cell RCCs. The subgroup analysis in ASSURE trial (Lancet Oncology 2016, EA E2805) did not show any benefit of adjuvant sunitinib or sorafenib in nonclear cell RCCs (including 111 patients with chromophobe &nbs...
Sign in or Register to read more